
Discovery
BIOSPECIMENS
~10,000s of analytes
<10s of biospecimens
(blood)
Untargeted platforms
~100s of Candidates
Gaps/barriers
•Many Candidates
•Prioritization uncertain
•No mechanism for attrition
•Few high-quality reagents
•Need for redefined discovery and bridging techniques
Qualification (clinical validation)
~10s of analytes
~1000s of biospecimens
Immunoassay
Panel of qualification biomarkers